Welcome to LookChem.com Sign In|Join Free
  • or
Hubei Jusheng Technology Co., Ltd.,Injectable Anastrozole Arimidex Steroid 120511-73-1for Anti-Estrogen and Breast Cancer Treatment//www.lookchem.com/300w//2010/0625/120511-73-1.jpg

Communicate with Supplier:

Ms. Linda
Ms. Linda: What can I do for you?

Injectable Anastrozole Arimidex Steroid 120511-73-1for Anti-Estrogen and Breast Cancer Treatment CAS NO.120511-73-1

FOB Price:
USD 1.00-1.00 /Gram Get Latest Price
Min.Order Quantity:
10 Gram
Wuhan / Shanghai / Guangzhou / Tianjin Port
Payment Terms:
L/C,T/T,Western Union,MoneyGram,Other

Add to Inquiry Cart

Product Details


  • astrozole
  • Arimidex
  • Aromasin

Quick Details

  • ProName: Injectable Anastrozole Arimidex Steroi...
  • CasNo: 120511-73-1
  • Molecular Formula: C17H11N5
  • Appearance: white crystalline powder
  • Application: medical intermediate
  • DeliveryTime: within a week
  • PackAge: A variety of packing ways for your cho...
  • Port: Wuhan / Shanghai / Guangzhou ...
  • ProductionCapacity: 200 Kilogram/Month
  • Purity: 98.5%
  • Storage: Kept in a well-closed, light-resistant...
  • Transportation: EMS, HKEMS, DHL, TNT, UPS, Fedex....
  • LimitNum: 10 Gram
  • Moisture Content: 0%
  • Impurity: 0.05%
  • Water content: 0%


1, high quality with competitive price:
we are manufacturer and can provide high quality products with factory price.
2, fast and safe delivery
1) parcel can be sent out within 24 hours after payment. tracking number available
2) secure and discreet shipment. various transportation methods for your choice
3, we have clients throughout the world.
1) professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.
2) market feedback and goods feedback will be appreciated, meeting customers's requirement is our responsibility.
3) high quality, competitive price, fast delivery, first-class service gain the trust and praise from the customers.


semi-finished injectable anastrozole (arimidex) cas 120511-73-1for anti-estrogen and breast cancer treatment

quick detail:


alias: arimidex

cas no: 120511-73-1

mf: c17h19n5

mw: 293.37

hplc injectable anti estrogen steroids anastrozole / arimidex , no side effects

purity: 98%

appearance: white powder.

manufacturer :yuanyang

other drugs in same class:anastrozole,letrozole,tamoxifen citrate,exemestane

usage: an aromatase inhibitor. used as an antineoplastic raw materials.

potent selective triazole aromatase inhibitors, can inhibit the cytochrome p-450 aromatase enzyme which depends blocking the biosynthesis of estrogen, and estrogen to stimulate breast cancer cell growth factors. treatment of breast cancer, especially for those with hormone relapse after adjuvant therapy after menopause for women with advanced breast cancer

product description:

1). arimidex (anastrozole) is the aromatase inhibitor of choice. arimidex’s mechanism of action — blocking conversion of aromatizable steroids to estrogen — is in contrast to the mechanism of action of anti-estrogens such as clomiphene (clomid) or tamoxifen (nolvadex), which block estrogen receptors in some tissues, and activate estrogen receptors in others.


1). anastrozole is prescribed for hormone receptor-positive, early breast cancer in postmenopausal women as adjuvant treatment ( treatment following surgery with or without radiation ). anastrozole is prescribed as a first-line treatment for hormone receptor-positive or hormone receptor unknown, locally advanced or metastatic breast cancer in postmenopausal women. anastrozole is also prescribed for the treatment of advanced breast cancer in postmenopausal women with disease progression following treatment with tamoxifen (nolvadex, soltamox).

2). arimidex is approved for adjuvant treatment (treatment following surgery with or without radiation) of postmenopausal women with hormone receptor-positive early breast cancer.

arimidex is approved for the initial treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of postmenopausal women with advanced breast cancer that has progressed following treatment with tamoxifen. patients with hormone receptor-negative disease and patients who did not previously respond to tamoxifen therapy rarely responded to arimidex.

Send a message direct to supplier(s)

Enter email or Member ID
Hubei Jusheng Technology Co., Ltd.,

-Enter between 20 to 2000 letters.English only. Word count:0 letter(s).
-We suggest you include in your inquiry a brief introduction to your company as well as your product requirements